ChemoCentryx, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘ChemoCentryx, Inc. – Product Pipeline Review – 2016’, provides an overview of the ChemoCentryx, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by ChemoCentryx, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of ChemoCentryx, Inc.

The report provides overview of ChemoCentryx, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses ChemoCentryx, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features ChemoCentryx, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate ChemoCentryx, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for ChemoCentryx, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding ChemoCentryx, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

ChemoCentryx, Inc. Snapshot 6

ChemoCentryx, Inc. Overview 6

Key Facts 6

ChemoCentryx, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

ChemoCentryx, Inc. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

ChemoCentryx, Inc. - Pipeline Products Glance 13

ChemoCentryx, Inc. - Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

ChemoCentryx, Inc. - Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

ChemoCentryx, Inc. - Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

ChemoCentryx, Inc. - Drug Profiles 18

CCR-23G - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

CCR-93G - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

CCX-140 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

CCX-168 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

CCX-354 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CCX-507 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

CCX-6239 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CCX-650 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CCX-771 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CCX-872 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CCX-9588 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CCX-991 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Antagonize CCR1 for Undisclosed Indication - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecule to Antagonize CXCR6 for Autoimmune, Oncology and Liver Diseases - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecule to Target C5aR for Undisclosed Indication - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

vercirnon sodium - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ChemoCentryx, Inc. - Pipeline Analysis 46

ChemoCentryx, Inc. - Pipeline Products by Target 46

ChemoCentryx, Inc. - Pipeline Products by Route of Administration 48

ChemoCentryx, Inc. - Pipeline Products by Molecule Type 49

ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action 50

ChemoCentryx, Inc. - Dormant Projects 52

ChemoCentryx, Inc. - Discontinued Pipeline Products 53

Discontinued Pipeline Product Profiles 53

CCX-832 53

vercirnon sodium 53

ChemoCentryx, Inc. - Locations And Subsidiaries 54

Head Office 54

Other Locations & Subsidiaries 54

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

ChemoCentryx, Inc., Key Facts 6

ChemoCentryx, Inc. – Pipeline by Indication, 2016 9

ChemoCentryx, Inc. – Pipeline by Stage of Development, 2016 11

ChemoCentryx, Inc. – Monotherapy Products in Pipeline, 2016 12

ChemoCentryx, Inc. – Phase III, 2016 13

ChemoCentryx, Inc. – Phase II, 2016 14

ChemoCentryx, Inc. – Phase I, 2016 15

ChemoCentryx, Inc. – Preclinical, 2016 16

ChemoCentryx, Inc. – Discovery, 2016 17

ChemoCentryx, Inc. – Pipeline by Target, 2016 47

ChemoCentryx, Inc. – Pipeline by Route of Administration, 2016 48

ChemoCentryx, Inc. – Pipeline by Molecule Type, 2016 49

ChemoCentryx, Inc. – Pipeline Products by Mechanism of Action, 2016 51

ChemoCentryx, Inc. – Dormant Developmental Projects,2016 52

ChemoCentryx, Inc. – Discontinued Pipeline Products, 2016 53

ChemoCentryx, Inc., Subsidiaries 54

List of Figures

List of Figures

ChemoCentryx, Inc. – Pipeline by Top 10 Indication, 2016 8

ChemoCentryx, Inc. – Pipeline by Stage of Development, 2016 11

ChemoCentryx, Inc. – Monotherapy Products in Pipeline, 2016 12

ChemoCentryx, Inc. – Pipeline by Top 10 Target, 2016 46

ChemoCentryx, Inc. – Pipeline by Route of Administration, 2016 48

ChemoCentryx, Inc. – Pipeline by Molecule Type, 2016 49

ChemoCentryx, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 50

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports